Midi Health vs Curex
Only one of these two will name the molecule on its pricing page, and only one publishes an ongoing tirzepatide rate at all — they are not the same one.
Midi Health
Editorial
$226/mo
Every table on Midi's pricing page is labeled "4-week supply", so the $165.90 injectable floor is $180 a calendar month and the $164.00 sublingual floor is $178. Shipping and supplies sit inside those figures and no membership fee is charged, so the term is what a buyer has to convert.
- Every dose on four ladders carries its own published price
- Shipping and supplies sit inside the medication price
- No membership fee is charged beside the medication cost
- The 4-week term is printed above each table rather than buried
- Prices buy 4 weeks, so a calendar year costs thirteen fills
- The pricing page names a drug class and never the molecule
- Compounding pharmacies are described but not named
- Brand-name GLP-1 prescriptions carry no published price
Pick it for: Wanting every milligram priced before the first appointment
Not for: Anyone who needs the molecule and the pharmacy named before ordering.
Curex
Editorial
$199/mo
Semaglutide and tirzepatide are each sold as a weekly injection and as an oral dissolving tablet, opening at $49 and $149 for a first month under a running sale. Every ongoing rate is anchored to one figure, from $199 a month, with no separate price published for any of the four products.
- Both molecules offered as an injection and as an oral tablet
- $0 membership fee and free shipping stated on the program page
- Available in all 50 states, with the California limit disclosed
- A full refund is offered if no prescription is issued
- No ongoing price is published for any individual product
- $199 is a floor covering four products with different opening rates
- The $49 and $149 figures cover the first month only
- No milligram strength is published and no pharmacy is named
Pick it for: A cheap first month, or a Californian limited to tablets
Not for: Anyone comparing tirzepatide on an ongoing monthly price.
Our verdict
Midi's tirzepatide tables never say tirzepatide: the pricing page sells a dual-action GLP-1/GIP by drug class, on a table whose unit is four weeks, and thirteen of those fit inside a calendar year. Curex names both molecules and then prices neither separately — its floor covers all four products, the tirzepatide opening month is $149, and no ongoing tirzepatide figure appears anywhere. California is the exception worth knowing: state rules limit Curex to the tablet.
What actually separates them
Midi Health and Curex differ on published price, states a milligram dose, names its pharmacy and where you can use it. The table summarizes those terms; confirm any details it does not cover with the provider.
Midi Health’s comparison figure is $27 higher than Curex’s — a 14% difference between the listed rates. These figures do not establish equivalent prescribed doses, supply or care. Confirm the selected product, full payment obligation and next charge.
At unchanged rates, a twelve-month illustration is about $2,388 at Curex against $2,712 at Midi Health — a difference of $324. This is not a quote for a year of care: actual charges depend on prescribed supply, purchase terms and renewals.
| Midi Health | Curex | |
|---|---|---|
| Published price | $226/mo | $199/mo |
| States a milligram dose | Yes | No |
| Names its pharmacy | Yes | No |
| Where you can use it | 50 states | All 50 states |
Before you choose either
The providers describe different service areas. Midi Health lists 5 states that Curex does not list — AK, AR, CT, HI, MA. Confirm your location and selected medication directly. A provider-wide footprint does not establish every treatment’s availability.
Only one of these two publishes a milligram dose, which makes a straight price comparison impossible: you can tell what each costs, but only one tells you what you get. Ask the other what dose its price buys before you commit, then set both numbers against every published price we hold. A seller that will not answer that question has told you something.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.